Amgen (AMGN) announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events, MACE, in high-risk adults without a prior heart attack or stroke, when added to statins or other low-density lipoprotein cholesterol, LDL-C-lowering treatments. Repatha is the first and only PCSK9 inhibitor to demonstrate a significant reduction of cardiovascular events as both high-risk primary and secondary prevention. The results were presented in a late-breaking session at the 2025 American Heart Association Scientific Sessions and simultaneously published in the New England Journal of Medicine.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Amgen price target raised to $315 from $305 at Cantor Fitzgerald
- Amgen Stock Overvaluation Concerns Amid Mixed Future Guidance and Pipeline Delays
- Quantum Computing News: IonQ Expands Global Network as Quantinuum Unveils New Quantum Computer
- Amgen Inc Reports Strong Q3 Earnings and Strategic Growth
- Midday Fly By: Broader market bought on dip after tech selloff